Tilray Brands (TLRY) Total Current Liabilities (2017 - 2026)
Tilray Brands (TLRY) posted Total Current Liabilities of $257.5 million for Q1 2026, down 0.68% on a QoQ basis from $259.3 million in Q4 2025.
Tilray Brands (TLRY) Total Current Liabilities (2017 - 2026) Analysis & Trends
Tilray Brands' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $257.5 million for Q1 2026.
- Quarterly Total Current Liabilities changed N/A year-over-year to $257.5 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $257.5 million (changed N/A YoY) and the FY2025 annual result came in at $280.3 million, down 6.31% from the prior year.
- Total Current Liabilities was $257.5 million for Q1 2026 at Tilray Brands, down from $259.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $537.3 million in Q3 2023 and bottomed at $257.5 million in Q1 2026.
- A 5-year average of $335.2 million and a median of $288.0 million in 2022 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 48.13% — and 2023, when it surged 96.62%.
- Tilray Brands' Total Current Liabilities stood at $426.5 million in 2022, then dropped by 7.39% to $395.0 million in 2023, then slipped by 29.49% to $278.5 million in 2024, then fell by 6.9% to $259.3 million in 2025, then dropped by 0.68% to $257.5 million in 2026.
- Business Quant data shows TLRY's Total Current Liabilities at $257.5 million in Q1 2026, $259.3 million in Q4 2025, and $267.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn | 257.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 257.54 Mn |
| Nov 30, 2025 | 259.32 Mn |
| Aug 31, 2025 | 267.63 Mn |
| May 31, 2025 | 280.30 Mn |
| Nov 30, 2024 | 278.52 Mn |
| Aug 31, 2024 | 293.55 Mn |
| May 31, 2024 | 299.17 Mn |
| Feb 29, 2024 | 329.10 Mn |
| Nov 30, 2023 | 394.99 Mn |
| Aug 31, 2023 | 537.27 Mn |
| May 31, 2023 | 432.98 Mn |
| Feb 28, 2023 | 469.68 Mn |
| Nov 30, 2022 | 426.51 Mn |
| Aug 31, 2022 | 273.26 Mn |
| May 31, 2022 | 280.34 Mn |
| Feb 28, 2022 | 282.43 Mn |
| Nov 30, 2021 | 314.93 Mn |
| Aug 31, 2021 | 526.83 Mn |
| May 31, 2021 | 401.24 Mn |
| May 31, 2020 | 119.90 Mn |